Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 4

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  capecitabine
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study

100%
Borysiewicz Z., Ryniewicz-Zander I.
OncoReview
|
2015
|
vol. 5
|
issue 4
A164-168
EN
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HER-1 and HER-2 tyrosine kinase receptors. Combined with capecitabine, it is administered in patients suffering from advanced breast cancer with HER-2 receptor overexpression. The present article analyses data obtained from medical records of 24 breast cancer patients treated with lapatinib and capecitabine in the years 2010–2015, in order to examine the treatment-related toxicity. The major adverse effects observed under treatment included diarrhoea, nausea, emesis, skin toxicity, and elevated transaminases. In 3 patients, grade 3 adverse events were reported, as assessed in accordance with CTCAE. The most frequent cause behind the cessation of treatment was disease progression. The analysis has indicated that lapatinib plus capecitabine is a well-tolerated treatment regimen.
2
Publication available in full text mode
Content available

Lapatinib in the treatment of advanced HER2-positive breast cancer

88%
Kuc-Rajca M., Walaszkowska-Czyż A.
OncoReview
|
2017
|
vol. 7
|
issue 3
144-149
EN
The overexpression of the HER2 receptor and its gene amplification are observed in c. 20% of newly diagnosed cases of breast cancer and associated with a more aggressive clinical course and poorer prognosis. New HER2-targeted drugs, such as lapatinib, pertuzumab and trastuzumab emtansine, significantly improve patient outcomes. The article reviews the role of lapatinib in HER-targeted therapy and describes the treatment sequence of two women with HER2-positive advanced breast cancer.
3
Publication available in full text mode
Content available

Lapatinib in the treatment of advanced HER2-positive breast cancer

88%
Kuc-Rajca M., Walaszkowska-Czyż A.
OncoReview
|
2017
|
vol. 7
|
issue 3
144-149
EN
The overexpression of the HER2 receptor and its gene amplification are observed in c. 20% of newly diagnosed cases of breast cancer and associated with a more aggressive clinical course and poorer prognosis. New HER2-targeted drugs, such as lapatinib, pertuzumab and trastuzumab emtansine, significantly improve patient outcomes. The article reviews the role of lapatinib in HER-targeted therapy and describes the treatment sequence of two women with HER2-positive advanced breast cancer.
4
Publication available in full text mode
Content available

Off-label drug use in breast cancer therapy

75%
Jankowski T., Urbaniak M.
OncoReview
|
2017
|
vol. 7
|
issue 2
83-87
EN
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have undergone randomized clinical studies and have been registered for that specific indication. However, a number of drugs are used in an off-label manner, i.e. outside the officially approved product specifications. The paper discusses the use of several off-label therapies in breast cancer in order to demonstrate that such treatment may be well-grounded and indeed turns out beneficial in many cases. It describes the use of liposomal doxorubicin in pre- and post-operative treatment, capecitabine for incomplete efficacy of preoperative treatment, and the administration of metronomic vinorelbine. Moreover, the paper is aimed at demonstrating the legal basis and the principles of marketing authorization of off-label drug use.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.